JCO Precision Oncology Conversations
By American Society of Clinical Oncology (ASCO)
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 1
Reviews: 0
Episodes: 60
Description
JCO Precision Oncology Conversations is a monthly podcast featuring conversations with authors of clinically relevant and significant articles published in the JCO Precision Oncology journal. JCO Precision Oncology Conversations is hosted by the journal's social media editor, Dr. Abdul Rafeh Naqash.
| Episode | Date |
|---|---|
|
JCO PO Article Insights: Genomic Risk Classifiers in Localized Prostate Cancer
|
Nov 26, 2025 |
|
DLL3 and SEZ6 Expression in Neuroendocrine Carcinomas
|
Nov 19, 2025 |
|
Somatic Mutations of Colorectal Cancer by Birth Cohort
|
Oct 29, 2025 |
|
Areas of Uncertainty in Pancreatic Cancer Surveillance
|
Oct 11, 2025 |
|
Lynch Syndrome Mortality in the Immunotherapy Era
|
Oct 11, 2025 |
|
JCO PO Article Insights: A Retrospective Analysis to Identify ICI-Sensitive Populations
|
Sep 30, 2025 |
|
Genomic Profile of Small Cell Bladder, Lung and Urothelial Cancer
|
Sep 24, 2025 |
|
JCO PO Article Insights: MUC16 Directed BiTE Therapy in Epithelioid Sarcoma
|
Aug 27, 2025 |
|
BRCA-Altered Uterine Sarcoma Treated with PARP Inhibitors
|
Aug 20, 2025 |
|
JCO PO Article Insights: Prognostic Gene Expression Signature and MYC Expression in Osteosarcoma
|
Jul 30, 2025 |
|
JCO PO Article Insights: Prognostic Gene Expression Signature and MYC Expression in Osteosarcoma
|
Jul 30, 2025 |
|
JCO PO Article Insights: Real-Time Monitoring in RCC with ctDNA
|
Jun 25, 2025 |
|
A Position Paper on ctDNA Testing in Clinical Trials
|
Jun 18, 2025 |
|
JCO PO Article Insights: TMB and Real-World ICI Outcomes in Melanoma
|
May 28, 2025 |
|
Effectiveness and Cost-Effectiveness of Gene Panels in Melanoma
|
May 21, 2025 |
|
JCO PO Article Insights: Exceptional Responders with Abexinostat and Pazopanib
|
Apr 30, 2025 |
|
Prognostic Artificial Intelligence Scores and Outcomes in Nonmetastatic Prostate Cancer
|
Apr 16, 2025 |
|
JCO PO Article Insights: Prognostic Artificial Intelligence Nonmetastatic Prostate Cancer
|
Mar 26, 2025 |
|
JCO PO Article Insights: Therapy of Infantile Midline Low-Grade Gliomas
|
Feb 20, 2025 |
|
Adagrasib Following Sotorasib-Related Hepatotoxicity
|
Feb 19, 2025 |
|
JCO PO Article Insights: ctDNA as a Prognostic Biomarker in EGC
|
Jan 29, 2025 |
|
Proteomics Predictor for Immunotherapy Benefit
|
Jan 15, 2025 |
|
Transcriptome and ctDNA Associates with Pembrolizumab Benefit
|
Dec 18, 2024 |
|
JCO PO Article Insights: Germline Pathogenic Variants in Renal Cell Carcinoma
|
Nov 27, 2024 |
|
Uptake of Aspirin Chemoprevention in Lynch Syndrome
|
Nov 15, 2024 |
|
JCO PO Article Insights: Talazoparib in Solid Tumors with BRCA1/2 Mutation
|
Oct 30, 2024 |
|
Transcriptomic Profiling of Non-Localized Prostate Cancer
|
Oct 16, 2024 |
|
JCO PO Article Insights: MCED Test Preferentially Detects High-Grade Prostate Cancers
|
Sep 25, 2024 |
|
Molecular Characteristics of Early-Onset Biliary Tract Cancer
|
Sep 18, 2024 |
|
JCO PO Article Insights: Publication Trends in JCO Precision Oncology
|
Aug 28, 2024 |
|
CCR Score to Predict ADT Benefit in Men with Prostate Cancer
|
Aug 21, 2024 |
|
JCO PO Article Insights: Statistical Considerations for Biomarker-Driven Oncology Clinical Trials
|
Jul 31, 2024 |
|
JCO PO Article Insights: Role of ctDNA in Appendiceal Cancer
|
Jun 26, 2024 |
|
PD-L1 Assay Concordance in Gastric Cancer
|
Jun 19, 2024 |
|
JCO PO Article Insights: Serial Post Operative ctDNA Predicts Poor Breast Cancer Outcome
|
May 29, 2024 |
|
Phase II Study of Erdafitinib in Tumors with FGFR Amplifications and Mutations or Fusions
|
May 15, 2024 |
|
JCO PO Article Insights: Web-Based Pretest Genetic Education for Prostate Cancer Germline Testing
|
Apr 24, 2024 |
|
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment
|
Apr 17, 2024 |
|
JCO PO Article Insights: Microsatellite Instability as a Biomarker in Clinical Practice
|
Mar 27, 2024 |
|
Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy
|
Mar 20, 2024 |
|
JCO PO Article Insights: Prediction of Adjuvant Pertuzumab Benefit by 80-GS
|
Feb 28, 2024 |
|
MultiCancer Detection Test Performance in Symptomatic Individuals
|
Feb 21, 2024 |
|
JCO PO Article Insights: Diverse Study Samples in Clinical Trials
|
Jan 31, 2024 |
|
Tumor Mutational Burden and Advanced Pancreatic Cancer
|
Jan 24, 2024 |
|
Representativeness of Lung-MAP Participants
|
Dec 20, 2023 |
|
Perspectives on Universal Germline Testing for Colorectal Cancer
|
Nov 22, 2023 |
|
Outcomes of the IMMray PanCan-d Test in High-Risk Individuals
|
Oct 26, 2023 |
|
Implementation of the Maine Cancer Genomics Initiative
|
Sep 20, 2023 |
|
Pertuzumab + Trastuzumab in Lung Cancer with ERBB2 Alterations
|
Aug 16, 2023 |
|
MMR-P Colorectal Cancer in Lynch Syndrome
|
Jul 19, 2023 |
|
Real-World NTRK Fusions and TRK Inhibitors in Veterans
|
Jun 21, 2023 |
|
Larotrectinib for TRK Fusion - Positive Lung Cancer
|
May 17, 2023 |
|
ctDNA for Recurrence Prediction in Esophagogastric Cancers
|
Apr 19, 2023 |
|
KRAS Variants, G12C, TMB, high PD-L1 Expression in Solid Tumors
|
Mar 15, 2023 |
|
Universal Genetic Germline Testing in Solid Tumor Cancer Patients
|
Feb 15, 2023 |
|
Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma, with Dr. Shilpa Gupta
|
Jan 18, 2023 |
|
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors, with Dr. Mark Stewart
|
Dec 21, 2022 |
|
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures with Dr. Mark Yarchoan
|
Nov 16, 2022 |
|
Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer with Dr. Thanh Dellinger
|
Oct 19, 2022 |
|
Introducing JCO Precision Oncology and Its Editor in Chief, Dr. James Ford
|
Sep 21, 2022 |